Top Analyst Upgrades and Downgrades: American Eagle, AOL, Boeing, Lululemon, Microsoft, ResMed, Vivint and More

Print Email

Stocks were recovering on Wednesday morning, perhaps after deciding that Tuesday’s early selling was too much. If the trend that has been in place in for almost four years now is not obvious, it is that investors have bought stocks on every single pullback.¬†They just keep looking for value and overlooked opportunities, or they buy their favorite stocks at every opportunity. 24/7 Wall St. reviews dozens of analyst research reports each day to find new trading and investment ideas for its readers. Some of these analyst calls cover stocks to buy, while other reports cover stocks to sell or to avoid.

These are Wednesday’s top analyst upgrades, downgrades and initiations.

American Eagle Outfitters, Inc. (NYSE: AEO) was raised to Outperform from Neutral with a $19 price target (versus a $16.22 close) at Cowen. Its consensus price target is closer to $18, with a 52-week range of $10.12 to $18.12.

AOL Inc. (NYSE: AOL) was downgraded to Sell from Buy at Cantor Fitzgerald. Goldman Sachs raised its rating to Neutral from Sell (oops!). Deutsche Bank downgraded the rating to Hold from Buy.

Boeing Co. (NYSE: BA) just had its investor conference and outlined ambitious production and financial targets, and shares closed at $145.43 on Tuesday. Sterne Agee CRT reiterated its Buy rating and $196 price target. Credit Suisse maintained its Neutral rating.

Lululemon Athletica Inc. (NASDAQ: LULU) was maintained as Buy with a $77 price target (versus a $64.70 close) at Sterne Agee CRT, effectively defending the stock after news of the departure of its head of Global Retail.

Microsoft Corp. (NASDAQ: MSFT) was raised to Buy from hold and the price target was set at $55 (versus a prior target of $44 and a $47.35 close) at Deutsche Bank.

ALSO READ: 11 Analyst Stocks Under $10 With Massive Upside Targets

ResMed Inc. (NYSE: RMD) was downgraded to Neutral from Buy at Bank of America Merrill Lynch, after news that its SERVE-HF trial has failed in sleep apnea and chronic heart failure and a safety signal arose in the trial.

Vivint Solar Inc. (NYSE: VSLR) was maintained as Buy at Merrill Lynch after earnings, but the price objective was cut to $23 from $24 (versus a $14.97 close) based on higher operating expenses.

Other key analyst upgrades, downgrades and initiations from Wednesday were seen as follows: